(redirected from Antibody-Mediated Rejection)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia.


Refusal by a bank to grant credit, usually because of the applicants financial history, or refusal to accept a security presented to complete a trade, usually because of a lack of proper endorsements or violation of rules of a firm.


1. A bank's refusal to grant a line of credit. This often applies to the refusal to grant a mortgage loan to an uncreditworthy person or a business loan to someone without a proper business plan.

2. An investor's refusal to accept a security presented to him/her/it. Reasons for this include suspicion of fraud or improperly filled-out forms.

3. Refusal to provide insurance coverage because the insurance company believes that the claim describes a service or situation that the policy does not cover.


The refusal to accept a security that has been delivered by a customer or broker. A questionable certificate or an improper endorsement are reasons for rejection.
References in periodicals archive ?
The ISHLTworking formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011).
Report from a consensus conference on antibody-mediated rejection in heart transplantation.
Time-dependent specificity of immunopathologic (C4d-CD68) and histologic criteria of antibody-mediated rejection for donor-specific antibodies and allograft dysfunction in heart transplantation.
Update on pathology of antibody-mediated rejection in the lung allograft.
Antibody-mediated rejection in liver transplantation: current controversies and future directions.
Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts," Transplantation, vol.
Table 1: Cases of antibody-mediated rejection treated with eculizumab.
The protocol is initiated at the time biopsy-proven acute antibody-mediated rejection is identified in the patient who prior to transplant had a negative XM.
2 mg/dl at one point, but there was no evidence of acute antibody-mediated rejection, only tacrolimus toxicity.
has had one episode of acute antibody-mediated rejection that occurred about 5 weeks after transplant and was successfully treated with steroids and additional plasmapheresis/CMV-HG.
1998) notes that donor age (> 53 years) and the occurrence of acute antibody-mediated rejection are important predictors of poor, long-term function.
Note: AMR = antibody-mediated rejection; CMV-HG = CMV hyperimmune globulin; DSA = donor specific antibody; HAR = hyperacute rejection; HLA = human leukocyte antigen; PP = plasmapheresis; XM = crossmatch Table 2 Rescue Therapy Protocol for Acute Antibody-Mediated Rejection Steps Purpose Establish +XM/elevated DSA titer.

Full browser ?